Scientific Plenary III: Cutting Edge Science|Michael McHale, MD, Moores UCSD Cancer Center, San Diego, CA| Volume 125, ISSUE 3, P771, June 2012

Download started.


Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

      Objective: To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is clinically inferior to the combination of doxorubicin, cisplatin, and paclitaxel (TAP) chemotherapy with regard to survival. To assess differences in toxicity profile, specifically neurotoxicity and infection between TAP and TC.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect